•Khazars
•Hapsburg
•Medici
•Romanovs
•Windsor
•Saxe-Coburg
•Bourbon
•Tudor
•Roman
•Plantagenet
•Hohenzollern
& others, you know who you are.
I forgive you. Let us be free… in Jesus name.
@FBIDirectorKash@FBI_Response Except for all the Epstein clients that are still walking free and reoffending.
They’ve got the full protection of the FBI.
Israel just carried out another horrific massacre in South Lebanon.
Dropping massive bombs near Jabal Amel Hospital in Tyre — wiping out 3 apartment blocks full of civilians.
People are still buried under the rubble.
This is an American-backed, American-funded genocide.
BREAKING: Largest Human Cancer Study of Ivermectin + Mebendazole Is Now PEER-REVIEWED and PUBLISHED in a MAJOR Cancer Journal
84.4% of cancer patients taking ivermectin + mebendazole for 6 months declared either CANCER DISAPPEARANCE, TUMOR REGRESSION, or CANCER STABILIZATION.
Our study, “Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort,” is now peer-reviewed and published in Anticancer Research—a major international oncology journal of the International Institute of Anticancer Research (IIAR), established in 1995.
The results represent one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology.
A diverse population of cancer patients (n=197) was prescribed compounded ivermectin–mebendazole through a U.S. telemedicine platform, with each capsule containing 25 mg ivermectin and 250 mg mebendazole.
Participants were followed for approximately six months using standardized digital surveys assessing cancer outcomes, medication adherence, and tolerability.
At approximately six months post-treatment initiation, we observed an 84.4% Clinical Benefit Ratio (CBR)—meaning more than four out of five patients reported either:
No evidence of disease (32.8%)
Tumor regression (15.6%)
or Cancer stabilization (36.1%)
Importantly, adherence was remarkably high, with 86.9% completing the initial prescription and 66.4% remaining on therapy at six months.
Side effects were predominantly mild and manageable, reported in 25.4% of patients (primarily gastrointestinal), with 93.6% of those experiencing side effects continuing treatment after minor dosing adjustments.
This groundbreaking peer-reviewed publication was made possible through a unique collaboration between The Wellness Company, the McCullough Foundation, and the Chairman of the President’s Cancer Panel—uniting real-world clinical data, frontline medical experience, and epidemiologic expertise to evaluate inexpensive, repurposed therapies with major translational potential.
With these extraordinarily promising results, double-blind, placebo-controlled clinical trials are now required.
In the meantime, many cancer patients are exercising their right to try.
@twc_health@McCulloughFund@IIAR_Journals@P_McCulloughMD@DrHarveyRisch@DrKellyVictory@jathorpmfm@drdrew@PeterGillooly@FosterCoulson
Trump’s DOJ drops all charges against Israeli biolab operator - likely on Netanyahu’s orders.
Zionists control America - you’re just a debt slave on their tax farm.
Trump just swore in Kevin Warsh as the new Chair of the Federal Reserve
Kevin’s father-in-law is Ronald Lauder
Ronald is the president of the World Jewish Congress
I’m sure it’s nothing…
The U.S. should NOT use propaganda on our citizens, but that prohibition was lifted in 2013!
Thank you @RepDavidRouzer for cosponsoring HR 5704 to repeal the 2013 Smith-Mundt Modernization Act.
I think Nick Fuentes is a fed.
Constant division, endless infighting, defending Epstein, then attacking a Christian man only to endorse a Jewish Democrat woman after saying the left wants us dead.
The contradictions never end.